deltatrials

Melanoma Trials in Southport, Australia

Conditions / Melanoma / Southport, Australia

Melanoma has been the subject of sustained clinical investigation across multiple research sites.

22 total trials for this combination

Showing top 10 of 22 trials

Trials

NCT ID Title Status Phase
NCT05352672 Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma ACTIVE_NOT_RECRUITING
NCT05665595 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) COMPLETED PHASE3
NCT03553836 Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) ACTIVE_NOT_RECRUITING PHASE3
NCT05858736 Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors ACTIVE_NOT_RECRUITING PHASE1
NCT05002569 A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma TERMINATED PHASE3
NCT02308020 A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain COMPLETED PHASE2
NCT01909453 Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma COMPLETED PHASE3
NCT02263508 Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma TERMINATED PHASE3
NCT04410445 Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence TERMINATED PHASE3
NCT03068455 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma COMPLETED PHASE3

Related Pages